Home HOME Neoplasma 2016 Neoplasma Vol.63, No.5, p.774-778,2016

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.63, No.5, p.774-778,2016

Title: Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model
Author: M. KLANOVA, T. SOUKUP, J. MOLINSKY, L. LATECKOVA, P. VOCKOVA, M. ALAM, J. ZIVNY, M. TRNENY, P. KLENER

Abstract: Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin lymphoma with adverse prognosis. It was demonstrated that alternation of CHOP and DHAP chemotherapy improved outcome of mantle cell lymphoma patients. However, which components of DHAP, cisplatin, cytarabine, or both, were responsible for the improved outcome remained unclear. To answer this question, antitumor efficacies of equally toxic doses of cytarabine, cisplatin, and three different combinations were compared in vivo using mouse xenograft models of mantle cell lymphoma. We demonstrated that cisplatin, alone or with cytarabine, is significantly superior to single-agent cytarabine in both eliminating lymphoma cells and suppressing their proliferation rate.

Keywords: mantle cell lymphoma (MCL), cisplatin, high-dose cytarabin, DHAP
Published online: 09-Sep-2016
Year: 2016, Volume: 63, Issue: 5 Page From: 774, Page To: 778
doi:10.4149/neo_2016_515


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.